X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GLENMARK PHARMA SHASUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 123.9 20.5 603.8% View Chart
P/BV x 8.5 3.6 237.7% View Chart
Dividend Yield % 0.2 0.3 79.7%  

Financials

 SHASUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GLENMARK PHARMA
Mar-18
SHASUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs94930 10.1%   
Low Rs46517 8.8%   
Sales per share (Unadj.) Rs214.2322.6 66.4%  
Earnings per share (Unadj.) Rs5.328.5 18.7%  
Cash flow per share (Unadj.) Rs15.839.2 40.4%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.3 517.7%  
Book value per share (Unadj.) Rs53.3183.0 29.1%  
Shares outstanding (eoy) m56.62282.17 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.2 14.5%   
Avg P/E ratio x13.125.4 51.6%  
P/CF ratio (eoy) x4.418.5 23.9%  
Price / Book Value ratio x1.34.0 33.1%  
Dividend payout %18.77.0 267.0%   
Avg Mkt Cap Rs m3,958204,206 1.9%   
No. of employees `000NA13.7 0.0%   
Total wages/salary Rs m2,16418,718 11.6%   
Avg. sales/employee Rs ThNM6,636.8-  
Avg. wages/employee Rs ThNM1,364.7-  
Avg. net profit/employee Rs ThNM586.1-  
INCOME DATA
Net Sales Rs m12,12791,031 13.3%  
Other income Rs m229914 25.1%   
Total revenues Rs m12,35691,945 13.4%   
Gross profit Rs m1,00916,154 6.2%  
Depreciation Rs m5943,019 19.7%   
Interest Rs m4152,856 14.5%   
Profit before tax Rs m23011,193 2.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-733,155 -2.3%   
Profit after tax Rs m3028,039 3.8%  
Gross profit margin %8.317.7 46.9%  
Effective tax rate %-31.728.2 -112.3%   
Net profit margin %2.58.8 28.2%  
BALANCE SHEET DATA
Current assets Rs m6,88469,887 9.9%   
Current liabilities Rs m8,45632,879 25.7%   
Net working cap to sales %-13.040.7 -31.9%  
Current ratio x0.82.1 38.3%  
Inventory Days Days6281 75.7%  
Debtors Days Days10893 115.0%  
Net fixed assets Rs m4,97028,892 17.2%   
Share capital Rs m113282 40.1%   
"Free" reserves Rs m2,87551,353 5.6%   
Net worth Rs m3,02051,635 5.8%   
Long term debt Rs m1,81741,418 4.4%   
Total assets Rs m13,347125,954 10.6%  
Interest coverage x1.64.9 31.6%   
Debt to equity ratio x0.60.8 75.0%  
Sales to assets ratio x0.90.7 125.7%   
Return on assets %5.48.6 62.1%  
Return on equity %10.015.6 64.3%  
Return on capital %13.315.1 88.2%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84336,317 16.1%   
Fx outflow Rs m2,1739,720 22.4%   
Net fx Rs m3,66926,598 13.8%   
CASH FLOW
From Operations Rs m39816,481 2.4%  
From Investments Rs m-1,635-10,133 16.1%  
From Financial Activity Rs m1,309-4,685 -27.9%  
Net Cashflow Rs m711,770 4.0%  

Share Holding

Indian Promoters % 39.2 48.3 81.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 6.9 52.2%  
FIIs % 17.6 34.4 51.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.5 377.1%  
Shareholders   20,750 56,727 36.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS